The Galloway Lab studies how human papillomaviruses (HPVs) and human polyomaviruses (HPyV), specifically Merkel Cell polyomavirus (MCPyV) contribute to the development of cancers, and how that information can be used to better prevent, diagnose or treat malignancies. We have taken a broad-based approach to studying these viruses employing state of the art molecular and immunologic tools, and collaborating with clinicians, epidemiologists and biostatisticians. Current work is focused in the following areas:
Scherer, E.M., Smith, R.A., Carter, J.J., Wipf, G.C., Gallego, D.F., Stern, M., Wald, A., Galloway, D.A. Analysis of memory B cell responses reveals suboptimal dosing schedule of a licensed vaccine. J. Infec. Dis. Jan 30;217(4):572-580. 2018.
Khanal, S., Galloway, D.A. High-risk human papillomavirus oncogenes disrupt the Fanconi Anemia DNA repair pathway by impairing foci formation and de-ubiquitinylation of FancD2. PLoS Pathogens PLoS Pathog. Feb 28;15(2):e1007442. 2019.
Dye, K.N., Welcker, M., Clurman, B.E., Roman, A., Galloway, D.A. Merkel Cell polyomavirus tumor antigens expressed in Merkel Cell carcinoma function independently of the ubiquitin ligases Fbw7 and b-TrCP. PLoS Pathogens, Jan 28;15(1):e10075. 2019